Drug intelligence / Profile preview

BDR-661

Development stage: Preclinical
Lead developer: MDimune
Modality: Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

BDR-661 is a preclinical **MSC-derived cell-derived vesicle** therapeutic being developed by BioDrone Therapeutics for **eye disease**. The program is listed in the company pipeline as part of BioDrone's CDV platform and falls within its next-generation cell therapy portfolio. Based on the disclosed modality, BDR-661 appears to use mesenchymal stem cell-derived extracellular vesicles to deliver bioactive cargo and paracrine regenerative or anti-inflammatory signals to ocular tissues, but **no specific molecular target, payload composition, formulation, or route of administration has been publicly disclosed**.

Other names: BioDrone Therapeutics CDV MSC-derived vesicle program for eye disease

Beyond the preview

Go deeper on BDR-661.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDR-661.

Explore the full profile